Oncology News Articles

▼ Show details

The latest Cancer and Oncology news articles published daily by MDLinx physician editors who comb through the top peer-reviewed clinical journals for the medical articles that will make a difference to you and your practice. Organized by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants can stay current on latest oncology topics, symptoms, treatments, risk factors in Cancer and Hematology.

New! >> Start your free Oncology Board Exam Prep course now.
Ranked, sorted, and summarized by MDLinx editors from the latest literature
Topics:

1 Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: A pooled analysis of individual patient data from four randomised controlled trials The Lancet Oncology, November 26, 2014    Clinical Article

2 Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial The Lancet Oncology, November 26, 2014    Clinical Article

3 First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors Journal of Clinical Oncology, November 26, 2014    Clinical Article

4 Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor–positive breast cancer: A trial of the Eastern Cooperative Oncology Group Journal of Clinical Oncology, November 26, 2014    Clinical Article

5 Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: A randomized phase II study Annals of Oncology, November 26, 2014    Clinical Article

6 Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer Cancer, November 26, 2014    Clinical Article

7 Blood neutrophil–lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4 Medical Oncology, November 26, 2014    Clinical Article

8 National survey of US oncologists' knowledge, attitudes, and practice patterns regarding herb and supplement use by patients with cancer Journal of Clinical Oncology, November 26, 2014    Clinical Article

9 A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage Annals of Oncology, November 26, 2014    Evidence Based Medicine    Review Article

10 Outcome determinants for transformed indolent lymphomas treated with or without autologous stem cell transplantation Annals of Oncology, November 26, 2014    Clinical Article

11 Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase 1/2 clinical trial Annals of Oncology, November 26, 2014    Clinical Article

12 Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: A European consensus position paper Annals of Oncology, November 26, 2014    Review Article

13 Leptomeningeal metastases in high-grade adult glioma: development, diagnosis, management, and outcomes in a series of 34 patients Frontiers in Neurology, November 26, 2014    Review Article

14 Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial Full Text European Urology, November 26, 2014    Clinical Article

15 Michigan urological surgery improvement collaborative: Patterns of care in the radiographic staging of men with newly diagnosed low risk prostate cancer The Journal of Urology, November 26, 2014    Clinical Article

16 Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date Medicinal Research Reviews, November 26, 2014    Clinical Article

17 Effect of surgical margin status after radical prostatectomy on health-related quality of life and illness perception in patients with prostate cancer Urologic Oncology: Seminars and Original Investigations, November 26, 2014    Clinical Article

18 How many cores should be taken in a repeat biopsy on patients in whom atypical small acinar proliferation has been identified in an initial transrectal prostate biopsy? Full Text International Braz J Urol, November 26, 2014    Clinical Article

19 Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: A systematic review and meta-analysis World Journal of Urology, November 26, 2014    Clinical Article

20 Parathyroid carcinoma in more than 1,000 patients: A population-level analysis Surgery, November 26, 2014    Clinical Article

50 available pages FirstPrevious 1 2 3 4 5 6 7 8 9 10 Next Last

Clinical Pearls in Oncology

Get reports via email to claim your reading activity at MDLinx as Category 2 CME (It takes less than a minute)

Highlights in Oncology

Loss of PTEN expression portends poor prognosis in IPMNs of the pancreas

As reported in Clinical Cancer Research, loss of PTEN in intraductal papillary mucinous neoplasms (IPMNs) of the pancreas (n=36) is associated with invasiveness and poor survival.

Increased incidence of second primary cancers in patients with salivary gland tumors

As reported in JAMA—Otolaryngology-Head & Neck Surgery, patients with salivary gland tumors have an increased risk of second primary tumors and newly developed cancers. Specifically, the cumulative 2-, 5-, and 10-year rates for second primary cancers are 4.4%, 8.3%, and 12.4%, respectively. Similarly, the cumulative 2-, 5-, and 10-year rates for newly diagnosed cancers are 1.1%, 3.4%, and 10.5%, respectively.

CTC count predicts survival in mBC

As reported in The Lancet Oncology, circulating tumor cell (CTC) quantification in patients (20 studies; n = 1944) with metastatic breast cancer (mBC) predicts progression-free survival (PFS) and overall survival (OS), especially when coupled with clinicopathologic data. A CTC count ≥ 5/7.5 mL at baseline is associated with decreased PFS (HR = 1.92) and OS (HR = 2.78). An elevated CTC count 3-5 weeks and 6-8 weeks after treatment commences is also associated with decreased PFS (HR = 1.85 and 2.20) and OS (HR = 2.26 and 2.91).


Other Topics in Oncology